Specialties

Promising new combination therapy for FL

Presented By

Dr Lorenzo Falchi , Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASH 2025

Type

News article

22 December 2025 16:01

Off-the-shelf CAR T-cell product under investigation in B-cell NHL

Presented By

Dr Jingwei Yu , Tianjin Medical University, China

Conference

ASH 2025

Type

News article

22 December 2025 16:00

Fixed-duration or continuous treatment for CLL?

Presented By

Dr Othman Al-Sawaf , University Hospital of Cologne, Germany

Conference

ASH 2025

Type

News article

22 December 2025 15:59

KITE-363 and KITE-753 fly far in LBCL

Presented By

Prof. Saurabh Dahiya , Stanford University School of Medicine, CA, USA

Conference

ASH 2025

Type

News article

22 December 2025 15:58

Pole-position data for pirtobrutinib in CLL/SLL

Presented By

Prof. Wojciech Jurczak , Maria Sklodowska Curie National Research Institute of Oncology, Poland

Conference

ASH 2025

Type

News article

22 December 2025 15:57

Does earlier cilta-cel treatment improve outcomes in MM?

Presented By

Prof. Luciano Costa , University of Alabama, AL, USA

Conference

ASH 2025

Type

News article

22 December 2025 15:51

Promising data for a novel, innovative bispecific antibody in MM

Presented By

Prof. Jin Lu , Peking University People’s Hospital, China

Conference

ASH 2025

Type

News article

22 December 2025 15:50

MajesTEC results for teclistamab plus daratumumab in MM

Presented By

Prof. María-Victoria Mateos , University of Salamanca, Spain

Conference

ASH 2025

Type

News article

22 December 2025 15:49

First data from in vivo CAR T-cell therapy in MM

Presented By

Prof. Phoebe Joy Ho , University of Sydney, Australia

Conference

ASH 2025

Type

News article

22 December 2025 15:48

New frontline therapy for AML?

Presented By

Prof. Amir Fathi , Harvard Medical School, MA, USA

Conference

ASH 2025

Type

News article

22 December 2025 15:47

New frontline regimen for Ph+ ALL tested in phase 3

Presented By

Prof. Suning Chen , First Affiliated Hospital of Soochow University, China

Conference

ASH 2025

Type

News article

22 December 2025 15:46

Can we use non-TBI conditioning regimens in selected B-cell ALL patients?

Presented By

Prof. Hisham Abdel-Azim , Loma Linda University Cancer Center, CA, USA

Conference

ASH 2025

Type

News article

22 December 2025 15:44

Meet the Expert: Prof. Rebecca Dent

Expert

Prof. Rebecca Dent, National Cancer Centre, Singapore

Conference

ESMO 2025

19 December 2025 10:04

VIKTORIA-1: PAM inhibition efficacious in HR+ HER2- PIK3CA wild-type aBC

Presented By

Dr Sara Hurvitz , Fred Hutchinson Cancer Center, WA, USA

Conference

ESMO 2025

Type

News article

15 December 2025 12:58

TROPION-Breast02: New standard-of-care for TNBC?

Presented By

Prof. Rebecca Dent , National Cancer Center, Singapore

Conference

ESMO 2025

Type

News article

15 December 2025 12:57

SERENA-6: Improved quality-of-life with novel treatment regimen in ESR1-mutated BC

Presented By

Dr Erica Mayer , Dana Farber Cancer Institute, MA, USA

Conference

ESMO 2025

Type

News article

15 December 2025 12:56

Clever strategy to increase uptake of pembrolizumab in TNBC

Presented By

Dr Atul Batra , All India Institute of Medical Science, India

Conference

ESMO 2025

Type

News article

15 December 2025 12:55

OptiTROP-Breast02: Sacituzumab tirumotecan meets phase 3 endpoints

Presented By

Dr Man Li , The second affiliated hospital of Dalian Medical University, China

Conference

ESMO 2025

Type

News article

15 December 2025 12:54

evERA BC: Convincing phase 3 results for all-oral treatment in ER+ HER2- aBC

Presented By

Dr Erica Mayer , Dana Farber Cancer Institute, MA, USA

Conference

ESMO 2025

Type

News article

15 December 2025 12:53

Excellent data for novel ADC trastuzumab botidotin in HER2-positive BC

Presented By

Prof. Xichun Hu , Fudan University Cancer Institute, China

Conference

ESMO 2025

Type

News article

15 December 2025 12:52

ASCENT-03: Sacituzumab govitecan proves its value in metastatic TNBC

Presented By

Dr Javier Cortes , International Breast Cancer Center, Spain

Conference

ESMO 2025

Type

News article

15 December 2025 12:48

DESTINY-Breast09: T-DXd plus pertuzumab performs well across subgroups in HER2+ BC

Presented By

Prof. Sibylle Loibl , University Hospital Goethe, German

Conference

ESMO 2025

Type

News article

15 December 2025 12:46

How to avoid adjuvant chemo in high-risk ER+ HER2- early BC?

Presented By

Prof. Paul Cottu , Institute Curie, France

Conference

ESMO 2025

Type

News article

15 December 2025 12:45

POSITIVE: No harmful effects of interrupting endocrine therapy for pregnancy in HR+ BC

Presented By

Dr Fedro Peccatori , European Institute of Oncology, Italy

Conference

ESMO 2025

Type

News article

15 December 2025 12:44

Large review on the value of clinical breast examination as a screening tool

Presented By

Dr Jack Atherton , The University of Manchester, UK

Conference

ESMO 2025

Type

News article

15 December 2025 12:44

Bone health in postmenopausal women with ER+ early BC

Presented By

Medical student Emily Gillespie , University of Southampton, UK

Conference

ESMO 2025

Type

News article

15 December 2025 12:43

DESTINY-Breast05: Trastuzumab deruxtecan performs well in high-risk HER2+ early BC

Presented By

Prof. Charles Geyer, University of Pittsburgh, PA, USA

Conference

ESMO 2025

Type

News article

15 December 2025 12:42

Strong antiproliferative effect of preoperative giredestrant in premenopausal ER+ HER2- BC

Presented By

Dr Antonio Llombart-Cussac , Arnau de Vilanova Hospital, Spain

Conference

ESMO 2025

Type

News article

15 December 2025 12:41

NATALEE: Continued benefit with ribociclib plus NSAIs in HR+ HER2- early BC at 5 years

Presented By

Prof. John Crown , St Vincent’s University Hospital, Ireland

Conference

ESMO 2025

Type

News article

15 December 2025 12:40

DESTINY-Breast11: Neoadjuvant T-DXd-THP safe and efficacious in high-risk HER2+ early BC

Presented By

Prof. Nadia Harbeck , Ludwig-Maximilians University Hospital, Germany

Conference

ESMO 2025

Type

News article

15 December 2025 12:39

monarchE: Abemaciclib improves OS in HR+ HER2- high-risk early BC

Presented By

Prof. Stephen Johnston, The Royal Marsden, NHS Foundation Trust, UK

Conference

ESMO 2025

Type

News article

15 December 2025 12:37

MajesTEC results for teclistamab plus daratumumab in MM

Presented By

Prof. María-Victoria Mateos , University of Salamanca, Spain

Conference

ASH 2025

15 December 2025 11:38

First data from in vivo CAR T-cell therapy in MM

Presented By

Prof. Phoebe Joy Ho , University of Sydney, Australia

Conference

ASH 2025

15 December 2025 11:25

Off-the-shelf CAR T-cell product under investigation in B-cell NHL

Presented By

Dr Jingwei Yu , Tianjin Medical University, China

Conference

ASH 2025

11 December 2025 10:55

New frontline regimen for Ph+ ALL tested in phase 3

Presented By

Prof. Suning Chen , First Affiliated Hospital of Soochow University, China

Conference

ASH 2025

11 December 2025 10:52

Promising new combination therapy for FL

Presented By

Dr Lorenzo Falchi , Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASH 2025

11 December 2025 10:37

New frontline therapy for AML?

Presented By

Prof. Amir Fathi , Harvard Medical School, MA, USA

Conference

ASH 2025

11 December 2025 10:33

Fixed-duration or continuous treatment for CLL?

Presented By

Dr Othman Al-Sawaf, University Hospital of Cologne, Germany

Conference

ASH 2025

9 December 2025 16:17

KITE-363 and KITE-753 fly far in LBCL

Presented By

Prof. Saurabh Dahiya, Stanford University School of Medicine, CA, USA

Conference

ASH 2025

9 December 2025 16:14

Does earlier cilta-cel treatment improve outcomes in MM?

Presented By

Prof. Luciano Costa , University of Alabama, AL, USA

Conference

ASH 2025

9 December 2025 16:11

Promising data for a novel, innovative bispecific antibody in MM

Presented By

Prof. Jin Lu , Peking University People’s Hospital, China

Conference

ASH 2025

9 December 2025 16:08

Durvalumab in combination with chemotherapy shows promise for patients with SCLC and poor performance status

Presented By

Prof. Satoshi Watanabe , Niigata University, Japan

Conference

ERS 2025

2 October 2025 11:07

Earlier skin cancer diagnosis and high patient satisfaction with patient-led teledermoscopy

Presented By

Dr Filip Mijovic , Princess Royal University Hospital, UK

Conference

EADV 2025

23 September 2025 13:40

Clinically meaningful and durable response of mosunetuzumab in MZL

Presented By

Dr Tara Graff, Mission Cancer and Blood, IA, USA

Conference

SOHO 2025

19 September 2025 16:51

Acalabrutinib Added to Bendamustine-Rituximab Improves Outcomes in High-Risk Untreated Mantle Cell Lymphoma

Presented By

Dr Victoria Otero , AstraZeneca, Gaithersburg, USA

Conference

SOHO 2025

19 September 2025 16:48

Glofitamab Shows High and Durable Remissions in Heavily Pretreated Mantle Cell Lymphoma

Presented By

Dr Estefania Mulvihill, F. Hoffman-La Roche, Switzerland

Conference

SOHO 2025

19 September 2025 16:45

Fixed-Duration Subcutaneous Mosunetuzumab Achieves High Response Rates and PK Non-Inferiority in Relapsed or Refractory Follicular Lymphoma

Presented By

Volker Wibking, MD , Genentech, CA, USA

Conference

SOHO 2025

19 September 2025 16:36

Epcoritamab Demonstrates Durable 3-Year Responses in Relapsed or Refractory Follicular Lymphoma

Presented By

Yasmin Karimi, MD

Conference

SOHO 2025

19 September 2025 16:32

Unravelling real-world safety and effectiveness of axi-cel in LBCL

Presented By

Dr Dasom Lee, Stanford University, CA, USA

Conference

EHA 2025

18 June 2025 11:23

inMIND: Positive phase 3 results for tafasitamab combination in FL

Presented By

Prof. Marek Trneny, Charles University, Czech Republic

Trial

Phase 3, inMIND

Conference

EHA 2025

18 June 2025 11:20

ELM-2: Survival benefit for patients with FL on odronextamab

Presented By

Prof. Stefano Luminari, University of Modena and Reggio Emilia, Italy

Trial

Phase 2, ELM-2

Conference

EHA 2025

18 June 2025 11:19

HCT Frailty Scale may refine allo-HCT selection process

Presented By

Dr Maria Queralt Salas, Hospital Clinic de Barcelona, Spain

Conference

EHA 2025

17 June 2025 10:36

RedirecTT-1: Dual antigen-targeting treatment associated with promising efficacy in EMD myeloma

Presented By

Dr Shaji Kumar, Mayo Clinic, MN, USA

Trial

Phase 2, RedirecTT-1

Conference

EHA 2025

17 June 2025 10:30

Large pooled analysis reveals prognostic utility of circulating tumour cells in MM

Presented By

Dr Luca Bertamini, University of Turin, Italy

Conference

EHA 2025

17 June 2025 10:29

GAIA/CLL13: Positive 5-year efficacy outcomes for GIV in CLL

Presented By

Dr Arnon Kater, Amsterdam UMC, the Netherlands

Trial

Phase 3, GAIA, CLL13

Conference

EHA 2025

16 June 2025 10:58

TUSCANY: Promising data for addition of tuspetinib in untreated chemo-ineligible AML

Presented By

Dr Gabriel Mannis, Stanford University, CA, USA

Trial

Phase 2, TUSCANY

Conference

EHA 2025

16 June 2025 10:55

STARGLO: Long-term clinical benefits of Glofit-GemOx over R-GemOx in DLBCL

Presented By

Dr Gareth Gregory, Monash University, Australia

Trial

Phase 3, STARGLO

Conference

EHA 2025

16 June 2025 10:52

A chemo-free second-line option for MET-amplified NSCLC

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 3, SACHI

Conference

ASCO 2025

5 June 2025 13:26

No added benefit of relatlimab in the adjuvant melanoma setting

Presented By

Dr Georgina Long, Melanoma Institute Australia

Trial

Phase 3, RELATIVITY-098

Conference

ASCO 2025

5 June 2025 13:16

Emerging intralesional therapies for BCC

Presented By

Dr Antonio Cozzio, Kantonsspital St Gallen, Switzerland

Conference

DDD 2025

Type

Peer-reviewed article

5 June 2025 11:30

Diagnosis and management of atypical melanocytic lesions

Presented By

Dr Willeke Blokx, University Medical Center Utrecht, the Netherlands

Conference

DDD 2025

Type

Peer-reviewed article

5 June 2025 11:16

Expanding treatment armamentarium for actinic keratosis and Bowen’s disease

Presented By

Dr Klara Mosterd, Maastricht University Medical Center, the Netherlands

Conference

DDD 2025

Type

Peer-reviewed article

5 June 2025 11:07

Benmelstobart-anlotinib combination superior to pembrolizumab in advanced NSCLC

Presented By

Dr Baohui Han, Shanghai Chest Hospital, China

Trial

Phase 3, CAMPASS

Conference

ASCO 2025

4 June 2025 11:32

Sacituzumab govitecan plus pembrolizumab outperforms chemotherapy in PD-L1+ metastatic TNBC

Presented By

Dr Sara M. Tolaney, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Trial

Phase 3, ASCENT-04, KEYNOTE-D19

Conference

ASCO 2025

2 June 2025 13:53

Vepdegestrant outperforms fulvestrant in ESR1-mutant aBC

Presented By

Dr Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN, USA

Trial

Phase 3, VERITAC-2

Conference

ASCO 2025

2 June 2025 13:51

Reduced biopsy rate and improved malignancy rate with high-end imaging tool

Presented By

Dr Jordan Phillipps, Washington University School of Medicine, MO, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:24

Cutaneous immune-related AEs may predict toxicities in ICI-treated patients

Presented By

Elle Kim, John Hopkins University, MD, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:19

Clinical patterns and outcomes in hypopigmented mycosis fungoides

Presented By

Dr Jong Bin Park, Kosin University, South Korea

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:10

InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

Presented By

Prof. Laurie Sehn, University of British Columbia, Canada

Trial

Phase 3, inMIND

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:34

High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

Presented By

Dr Jing-Zhou Hou, University of Pittsburgh Medical Center, PA, USA; Dr Sameh Gaballa, Lee Moffitt Cancer Center, FL, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:31

Excellent CR rates for venetoclax plus pola-R-CHP in BCL2-positive DLBCL

Presented By

Dr Catherine Diefenbach, NYU Langone Health, NY, USA

Trial

Phase 1, BO42203

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:29

ATALANTA-1: Promising data for novel CAR T-cell therapy

Presented By

Prof. Marie José Kersten, Amsterdam University Medical Center, the Netherlands

Trial

Phase 1/2, ATALANTA-1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:27

ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Presented By

Prof. Sattva Neelapu, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, ZUMA-5

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:25

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Presented By

Dr Timothy Fenske, Medical College of Wisconsin, WI, USA

Trial

Phase 3, EA4151

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:23

Quizartinib maintenance therapy crucial for FLT3-ITD-positive AML

Presented By

Prof. Mark Levis, Johns Hopkins University, MD, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:20

Revumenib combination therapy associated with high response rates in relapsed/refractory AML

Presented By

Dr Ghayas Issa, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2, SAVE

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:17

Venetoclax plus azacitidine in young patients with AML

Presented By

Dr Daniel Pollyea, University of Colorado, CO, USA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:14

Promising results for ivosidenib-based triplet therapy in IDH1-mutated malignancies

Presented By

Dr Jennifer Marvin-Peek, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:12

CPX-351 outperforms FLAG-Ida in AML/MDS and MDS-related mutations

Presented By

Dr Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust, UK

Trial

Phase 3, AML19

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:09

High MRD-negativity rates for venetoclax plus ‘7+3’ chemotherapy in newly diagnosed AML

Presented By

Dr Ioannis Mantzaris, Montefiore Medical Center, NY, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:07

Findings from phase 3 uproleselan study in AML not all negative

Presented By

Prof. Daniel DeAngelo, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:05

Menin inhibitors on the rise in KMT2Ar acute leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:03

New standard-of-care for paediatric B-cell ALL

Presented By

Dr Rachel Rau, University of Washington, WA, USA

Trial

Phase 3, AALL1731

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:57

KCRd offers overall survival benefit over CRd in newly diagnosed MM

Presented By

Dr Charlotte Pawlyn, Institute of Cancer Research, UK

Trial

Phase 3, Myeloma XI/XI+

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:53

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, AQUILA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:49

Emerging mezigdomide-based options for heavily pre-treated MM

Presented By

Prof. Luciano Costa, University of Alabama at Birmingham, AL, USA

Trial

Phase 1/2, CA057-003

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:47

IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

Presented By

Prof. Salomon Manier, University of Lille, France

Trial

Phase 3, IFM2017-03

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:44

CEPHEUS: Further support for daratumumab regimens in untreated MM

Presented By

Prof. Sonja Zweegman, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, CEPHEUS

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:42

Margetuximab does not improve pCR rate in HER2-positive early breast cancer

Presented By

Dr Adrienne Waks, Dana-Farber Cancer Institute, USA

Trial

Phase 2, MARGOT/TBCRC052

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:37

Obesity is associated with worse prognosis in early-stage breast cancer

Presented By

Dr Hongchao Pan, University of Oxford, UK

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:35

T-DXd outperforms T-DM1 regardless of baseline genomic alterations in HER2-positive metastatic breast cancer

Presented By

Dr Paolo Tarantino, Dana-Farber Cancer Institute, USA

Trial

Phase 3, DESTINY-Breast03

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:33

Immediate surgery can offer long-term benefits for elderly patients with early-stage breast cancer

Presented By

Prof. Robert Hills, University of Oxford, UK

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:33

Long-term benefit of olaparib seen in high-risk early BRCA1/2-mutated breast cancer

Presented By

Prof. Judy Garber, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, OlympiA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:31

Encouraging results of neoadjuvant SHR-A1811 in the treatment of HER2-positive breast cancer

Presented By

Dr Junjie Li, Fudan University Cancer Hospital, China

Trial

Phase 2, FASCINATE-N

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:30

Active monitoring is a viable option for patients with low-risk DCIS

Presented By

Prof. Eun-sil Hwang, Duke University School of Medicine, NC, USA

Trial

COMET

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:28

Additional CDK4/6 inhibition in HER2-positive patients achieves clinically meaningful outcomes

Presented By

Dr Otto Metzger, Dana-Farber Cancer Institute, USA

Trial

Phase 3, AFT-38 PATINA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:23

NATALEE: Success with adjuvant ribociclib leads to FDA approval in early breast cancer

Presented By

Dr Jennifer Gao, CDER, U.S. Food and Drug Administration, USA

Trial

Phase 3, NATALEE

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 12:00

Inavolisib: The first FDA-approved treatment for use in a triple combination for metastatic breast cancer

Presented By

Dr Suparna Wedam, CDER, U.S. Food and Drug Administration, USA

Trial

Phase 3, INAVO120

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:58

Imlunestrant monotherapy improves PFS in ESR1-mutated patients, not in the overall population

Presented By

Dr Komal Jhaveri, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, EMBER-3

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:54

Neoadjuvant niraparib plus dostarlimab shows pCR benefit in BRCA-mutated, ER-positive/HER2-negative breast cancer 

Presented By

Dr Erica Mayer, Dana-Farber Cancer Institute, USA

Trial

Phase 2, TBCRC 056

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:50